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Fragments of mitochondrial DNA (mtDNA) are released outside the cell and they
appear to persist in extracellular fluids as circulating, cell-free, mtDNA (ccf-mtDNA).
When compared to nuclear DNA, such a double stranded mtDNA is more resistant
to nuclease degradation. In fact, it is stable extracellularly where it can be detected
in both plasma and cerebrospinal fluid (CSF), here acting as a potential biomarker in
various disorders. In neurological diseases (Alzheimer’s disease, Parkinson’s disease and
end-stage progressive Multiple Sclerosis), a decreased amount of CSF ccf-mtDNA is
related with progressive cell dysfunction. This suggests an alteration in neuronal mtDNA
levels (mtDNA replication, degradation and depletion) in vulnerable brain regions at early
stages of neurodegeneration leading to reduced mtDNA release, which takes place
before actual cell death occurs. On the other hand, elevated CSF ccf-mtDNA levels
are reported in acute phases of relapsing-remitting Multiple Sclerosis (RRMS). This
occurs during acute inflammation, which anticipates the neurodegenerative process.
Thus, an increase in inflammatory cells in the affected regions is expected to add on
mtDNA release into the CSF. In addition, similarly to bacterial DNA, the non-methylated
CpG sites of mtDNA, which activate innate immunity and inflammation, are likely to
participate in the molecular mechanisms of disease. Thus, ccf-mtDNA may represent
a powerful biomarker for disease screening and prognosis at early stage, although
its biological role may extend to generating the neurobiology of disease. The present
manuscript discusses recent experimental findings in relationship with clinical evidence
comparing neuro-immunological features of neurodegenerative disorders with frankly
neuro-infectious diseases.
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INTRODUCTION
Within eukaryotic cells, mitochondria play an important role
in energy metabolism, generation of free radicals, calcium
homeostasis, and apoptosis (1). Each cell may contain up to
thousands of mitochondria being each mitochondrion gifted
with its own genome (mtDNA), which replicates independently
of nuclear DNA (2). In humans, mtDNA is significantly smaller
when compared with nuclear DNA (16.569bp vs. 3.2 billion
bp), and it possesses only 37 genes, among which 13 encode
proteins belonging to the respiratory electron transport chain (3).
Unlike nuclear DNA, mtDNA is devoid of protective histones
and sophisticated DNA repair mechanisms, which makes it
vulnerable to genotoxic stimuli including oxidative stress (4,
5). In fact, high levels of reactive oxygen species (ROS) are
generated around mtDNA during oxidative phosphorylation
occurring in mitochondria. Such an oxidative environment
contributes to a high susceptibility of mtDNA to mutagenesis.
In fact, mtDNA possesses roughly a 10- to 200-fold higher
rate of mutagenesis than nuclear DNA under a comparable
oxidative stress environment. This may be detrimental for
those high-energy-demanding and post-mitotic cells including
neurons and myocytes, which are mostly sensitive to altered
respiratory chain activity and ROS-mediated damage yielded
by mtDNA changes (6). Such a specific vulnerability of
mtDNA determines the occurrence of a detectable amount of
mitochondrial DNA fragments, which are released into the
bloodstream as circulating, cell-free fragments (ccf-mtDNA).
These correspond to double-stranded DNAmolecules, which are
biologically fragmented into both short (lower than 1Kb) and
long (up to 21 kb) segments (7). Due to a striking structural
similarity which is evolutionary derived from bacterial DNA,
mtDNA fragments activate innate immunity and inflammation
through a common molecular pathway operating in a number
of etiologically different disorders (4, 8–12). In this way, ccf-
mtDNA generate key, yet double-faceted inflammatory responses
including antimicrobial immunity and neuro-immunological
disorders. As for most molecules involved in the immune
response, the bulk of evidence concerning the measurement
of ccf-mtDNA and its role in physiology and disease stems
from studies carried out outside the CNS. In fact, ccf-
mtDNA has been analyzed in various clinical conditions
like neoplasia, trauma, infections, stroke and cardiovascular
diseases, where it has been tested as diagnostic and predictive
biomarker. Only recently, mtDNA started being evaluated in
neurological disorders of both sterile and infectious origin.
In line with the higher resistance of mtDNA to nuclease-
dependent degradation compared with nDNA (13), mtDNA
persists as ccf-mtDNA within extracellular fluids including the
CSF. Thus, ccf-mtDNA may be a potential biomarker of cell
death and non-specific tissue injury; if further validated, in
the near future this is supposed to become an innovative
diagnostic tool in early stage screening and prognosis of several
disorders (7). Nonetheless, the biological role of ccf-mtDNA
and its fragments is still controversial and it needs to be fully
understood. Therefore, in the present manuscript we discuss
the role of ccf-mtDNA as a potential link between the brain
and immune system, which may provide novel insights into
neurological disorders.
ccf-mtDNA AND NEURO-INFECTIONS
Mitochondria are evolutionarily derived from energy-producing
alpha-bacteria, engulfed by archezoan cells approximately 2
billion years ago leading to a symbiotic relationship that built
up eukaryotic cells (14). Mitochondria share several features
with bacteria, including the double-membrane structure and
a circular genome which replicates independently of nuclear
DNA and possesses non-methylated CpG sites. In the light of
such a similarity, once released in either cytosol or extracellular
space, mtDNA fragments behave as danger-associated molecular
patterns (DAMPs) to activate innate immunity and inflammation
just like pathogen-associated molecular patterns (PAMPs). This
occurs through a molecular cascade which consists of binding
to Toll-like receptor 9 (TLR9) and subsequent activation of
the stimulator of interferon genes (STING) pathway (9–11, 15).
(Figure 1). Therefore, DAMPs accumulation activates resident
macrophages and fosters tissue infiltration by leukocytes (16, 17).
Such an overlapping molecular mechanism between DAMPs
and PAMPs may also lead to indistinguishable clinical responses
following infective and non-infective insults, as exemplified by
neurological and even systemic inflammatory syndromes (18–
20). In this context, while the detection of pathogen-associated
genome remains seminal for the clinical diagnosis, quantification
of ccf-mtDNA is emerging as a biomarker of tissue damage
and/or disease severity induced by pathogens. For instance,
increased levels of ccf-mtDNA and iron biomarkers are detected
in CSF and plasma from untreated HIV-infected patients,
which associates with HIV viral load and mild neurocognitive
impairment (20–22). This suggests that active viral replication
perturbs mitochondrial integrity leading to a progressive
extrusion of mtDNA fragments. Contrariwise, meningitis-related
pathogens (Streptococcus pneumonia and Neisseria meningitis)
produce a dramatic mitochondrial depletion and dysfunction,
which associates with decreased plasma mtDNA levels and
a less efficient antimicrobial immune response assessed in
animal models (23–25). Likewise, a quite selective mitochondrial
damage and reduction in mtDNA levels is detected in autopsy
brains from Herpes simplex (HSV-1) encephalitis patients
(26), though studies quantifying ccf-mtDNA in this specific
case are still missing so far. Nonetheless, these findings
suggest that a correlation between ccf-mtDNA levels and
disease severity stems from the degree of mitochondrial
impairment and mtDNA damage. It is likely that in the
early phase of infection, when mitochondrial and plasma
membrane damage is slight, the spread of ccf-mtDNA serves
as an attempt to activate antimicrobial immunity (27) and
to guarantee the preservation of mitochondrial function by
removing dysfunctional mtDNA fragments. In fact, even when
the plasmamembrane is intact, fragments of mutatedmtDNA are
compartmentalized within cytosolic organelles such as exosomes
and then released extracellularly along with other constituents
such as micro RNA (miRNA) (28). This latter mechanism
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FIGURE 1 | An overview of mtDNA fragments life: from their generation to spreading and their role as DAMPs in inflammation. Following cellular stress/injury (1)
mitochondria are compromised due to either a direct damage or an increased attempt to cope with metabolic cell demand. Thus, an increased amount of ROS in the
three complexes of the respiratory chain, directly affects mtDNA integrity (2). This leads to the accumulation of oxidized mtDNA fragments, which along with ROS, are
released in the cytosol as free molecules or engulfed into mitochondrial derived vesicles (MDV). The accumulation of mtDNA within a highly oxidative environment is
likely to overcome the attempt of autophagy to digest damaged mitochondria and mtDNA fragments (3). This leads to the spreading of free- or exosomes/MDV
engulfed- mtDNA fragments in the extracellular space (4). At the same time, intracellular mtDNA fragments trigger an inflammatory response already within the cytosol.
In fact, mtDNA behave as DAMPs to activate TLR9 on the endo-lysosomal membrane (5). This promotes the activation of NFkB and the transcription of
pro-inflammatory genes such as interferons (INFs) and pro-interleukines (ILs). Such an effect is magnified by an mtDNA-depended activation of two other components
(6, 7), the nucleotide-binding oligomerization domain (NOD)-like receptor family pyrin domain containing-3 (NLRP3) (inflammasome) and the stimulator of interferon
genes (STING) system. In this way, cytokines including IFN3/7 and IL-1β are produced and released extracellularly along with cell-free mtDNA. ccf-mtDNAs are spread
into the bloodstream where they add on IL-1β activity to recruit and activate leucocytes while promoting tissue leukocyte infiltration (8a). Within blood leucocytes,
ccf-mtDNA behave as DAMPs to promote inflammatory reaction, which favors cytokines release from the blood (9a). Again, ccf-mtDNA are spread within neighboring
cells (such as tissue resident macrophages), either via exosome endocytosis or via binding to receptors for advanced glycated end-products (RAGEs) (8b). This is key
to activate macrophages and fuel mtDNA-TLR9 dependent inflammation (9b). The result of such a domino-like cascade promoted by ccf-mtDNA is a vicious
inflammatory cycle, which fosters tissue and cell injury along with progressive mitochondrial damage (1).
would guarantee the preservation of mitochondrial function by
removing dysfunctional mutated DNA fragments (29–31). This
is supported by recent work from C. elegans neurons, which
expel dysfunctional mitochondria when exposed to neurotoxic
stress (31). On the other hand, persistent or severe insults of
either oxidative or infective nature can damage cell integrity
while producing apoptosis or necrosis, which is considered
as the main mechanism leading to mtDNA extrusion from
the cell or release into the blood (32, 33). Once released
extracellularly, mtDNA fragments may also act as toxic molecules
that further impair mitochondrial function, cell integrity and
tissue repair (34). It is remarkable that the role of ccf-mtDNA
as a potential biomarker extends beyond infectious disorders
to encompass neurodegenerative and neuro-immune disorders,
where the double-faceted mechanisms of ccf-mtDNA release are
very much recapitulated.
ccf-mtDNA AND NEURODEGENERATION
Recent studies linked the amount of CFS ccf-mtDNA to
neurodegeneration in patients affected by Alzheimer’s disease
(AD) and Parkinson’s disease (PD). In detail, a low concentration
of ccf-mtDNA was reported in the CSF of asymptomatic subjects
with familial and sporadic AD, suggesting that an alteration
in mtDNA replication or degradation precedes biomarkers of
neuronal damage in AD (30). In fact, a reduction in the
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amount of mtDNAwithin pyramidal neurons in AD hippocampi
parallels the reduction of ccf-mtDNA levels in early-stages of
AD. Unfortunately, other studies failed to replicate these data
on a large series of well-characterized cohorts of AD patients
(35). Nonetheless, a significant reduction of CSF ccf-mtDNA
was recently reported in sporadic PD patients, suggesting that
reduced CSF ccf-mtDNA may be a biomarker for early stages
of neurodegeneration (36). The specific role of reduced ccf-
mtDNA remains unknown (37, 38). The occurrence of reduced
amount of ccf-mtDNA in neurodegenerative disorders may
appear as a contradiction when considering the occurrence
of cell death, which is expected to massively release mtDNA.
This would elevate rather than depress ccf-mtDNA levels. This
contradiction is even stronger when considering that apoptotic
cell death, which occurs in neurodegeneration, should further
elevate the occurrence of mtDNA levels within dying neurons.
Therefore, it is unexpected that in PD and AD low ccf-
mtDNA levels are detected. Such a contradiction turns out to be
only apparent since mitochondria, as well as neuronal mtDNA
levels, are reduced during early stages of cell pathology. Thus,
it is likely that a suppression of baseline release of mtDNA
occurs following mitochondrial loss. This would explain why
low ccf-mtDNA levels, which may anticipate the occurrence of
neuronal death, are detected at early stages of neurodegeneration.
This is supported by studies showing that reduced neuronal
mtDNA copy number in neurodegenerative disorders is related
with a reduction in cell energy (38, 39). Remarkably, tissue-
specific depletion of mtDNA occurs in PD and AD patients
compared with age matched controls (40, 41). In detail,
in dopaminergic (DA) substantia nigra neurons of healthy
individuals, mtDNA copy number increases with age in order
to maintain the pool of wild-type mtDNA population in spite
of accumulating deletions (42). Such an upregulation fails
to occur in PD patients, resulting in depletion of wild-type
mtDNA (42) and an increase in mtDNA deletions (40, 43).
This very samemechanism characterizes hippocampal pyramidal
neurons in AD patients, where a reduction in mtDNA levels
goes along with an increase in mtDNA deletions (41, 44).
Studies quantifying the amount of ccf-DNA in neurodegenerative
disorders are still limited, thus the clinical significance remains
to be elucidated. Likewise, experimental studies are needed
to disclose the molecular mechanisms bridging ccf-mtDNA
with neurodegeneration. Experimental studies suggest that a
dysfunction of Parkin and PINK1-related mitophagy may be
key in contributing to mitochondrial decline and accumulation
of mtDNA mutations in DA neurons of sporadic PD (45).
This was assessed in mice homozygous for a proofreading
deficiency in DNA polymerase gamma (PLOG), which leads
to mitochondrial dysfunctions and progressive accumulation of
mtDNA mutations/deletions. As recently demonstrated, PLOG
precludes the formation of mtDNA deletions by degrading linear
mtDNA fragments (46), which would otherwise be released as
ccf-mtDNA. Several patients with POLGmutations and multiple
mtDNA deletions also present with early onset parkinsonism
(47). However, Pickrell et al. (45) demonstrated that a frank
loss of DA neurons recapitulating PD in POLG mutated
mice, occurs only following Parkin deletion. This suggests that
Parkin-mediated mitophagy compensates for mtDNA mutations
by rescuing mitochondrial functions to grant DA neuron
survival. The role of mitophagy in mitochondrial turnover and
ccf-mtDNA release appears critical also in LRRK2-related PD.
In fact, ccf-mtDNA emerged as a potential pathophysiological
marker in PD patients with p.G2019S mutation in LRRK2
(48), which affects mitochondrial function/dynamics by slowing
down mitophagy (49–51). Variant p.G2019S has a reduced age-
dependent penetrance (52), but the mechanisms whereby a
significant percentage of asymptomatic LRRK2mutation carriers
never develop PD remain unknown. Intriguingly, Podlesniy et al.
(48) showed that p.G2019S carriers with PD exhibit a higher
concentration of mtDNA in CSF, compared with asymptomatic
carriers and with idiopathic PD patients. These findings suggest
that different biochemical, and inflammatory pathways may
underlie the significance of ccf-mtDNA as a biomarker of
neurodegeneration in different forms of PD. Studies on other
neurodegenerative disorders suggest that the disease stage plays
a seminal role. In fact, ccf-mtDNA has been analyzed in multiple
sclerosis (MS), a neurodegenerative disorder possessing a strong
inflammatory response. When ccf-mtDNA were analyzed in
ventricular CSF (vCSF) at end-stage of progressive multiple
sclerosis (PMS), when neurodegeneration is pronounced, ccf-
mtDNA levels were depressed. This is consistent with other
neurodegenerative disorders such as AD and PD (29, 30).
In line with this, when compared with other markers for
neurodegenerative disease, the reduction in ccf-mtDNA occurs
concomitantly with an increase in the levels of glial fibrillary
acidic protein and S100 calcium binding protein B (53).
ccf-mtDNA LEVELS ARE ELEVATED IN
NEUROLOGICAL DISEASES WHEN
STRONG INFLAMMATION IS PRESENT
The role of mtDNA is emerging in immune-mediated
inflammatory diseases outside the CNS, such as rheumatoid
arthritis. In this chronic relapsing disorder, autoimmune
response mostly affects the joints and mtDNA has been detected
both in plasma and synovial fluid (54). Intra-articular injection
of oxidized mtDNA, but not nuclear DNA, triggers inflammatory
arthritis in mice (55). There are now numerous studies using
in vivo injection of mtDNA to provoke local and/or systemic
inflammation (8, 56–58). This is not surprising since mtDNA
contributes to inflammation at multiple levels when tissue or cell
homeostasis is perturbed. In fact, damaged mtDNA released into
the cytosol activate the inflammasome and NF-κB by binding
to TLR9 (9, 10, 12, 59). Moreover, mtDNA, which is released
in the cytosol due to mitochondrial stress, activates the STING
pathway and fosters the production of cytokines (4, 11, 60).
Noteworthy, this occurs along with pentraxin-3 release (61),
which is a strong modulator of the neuro-immune response
(62, 63). Remarkably, in contrast to neurodegeneration, which
associates with a reduction of CSF ccf-mtDNA, CNS disorders
featuring a strong inflammatory response are characterized
by elevated plasma mtDNA levels. In fact, elevated CSF ccf-
mtDNA occur in relapsing-remitting MS (RRMS) (64, 65),
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which possess an acute inflammatory response (66). Thus, it
is likely that the increase in ccf-mtDNA observed in RRMS is
a direct consequence of increased activation of inflammatory
cells, which release mtDNA into the CSF (67). A persistent
inflammatory reaction may recruit circulating immune cells,
while triggering a systemic response through the activation of
mtDNA-induced inflammatory pathways. In this way, a vicious
circle occurs where inflammatory cytokines and ROSmay induce
further damage to mitochondria and mtDNA. In this scenario,
elevated ccf-mtDNA concentration in MS may reflect early,
active inflammatory activity, which eventually culminates in
mitochondrial damage, neural loss and brain atrophy (65). In
this condition, the measurement of ccf-mtDNA concentration
configures as a potential biomarker for acute inflammatory
stress. Whether this phenomenon is specific for MS or it rather
reflects generic neuro-inflammation, still needs to be investigated
(64). Since mitochondrial damage occurs in active MS lesions
(68), one could speculate that mtDNA in the CSF may act as a
DAMP. Considering mtDNA as a DAMP in MS, may explain
the “inside-out theory” which suggests that inflammation is
secondary to a primary intrinsic process within neurons or other
cells such as oligodendrocytes (69). This neuro-immune concept
consists in the formation of intracellular compounds, which
trigger biochemical cascades leading to immunity activation
(inflammasome) which once released from the cell recruit in
turn a focal immune response. In this scenario, the “inside”
mtDNA fragment would be the inflammatory stimulus, which
clusters the intracellular cascade leading to a molecular complex,
which triggers the immune response. Once such a complex is
exposed “out” of the cell, immunity is strongly activated. This
is supported by studies showing that ccf-mtDNA may be useful
as a biomarker to predict treatment outcomes in MS. In fact,
compared with untreated patients, decreased levels of mtDNA
occur in patients receiving fingolimod, which limits autoreactive
inflammation in the CNS by acting on sphingosine-1-phosphate
(S1P) receptors, which are present on peripheral immune- as
well as glial and nerve cells (65). This warrants for further
studies focusing on disease modulatory treatments in order to
understand how they affect ccf-mtDNA levels, inflammation and
CNS cell injury.
FIGURE 2 | The crosstalk between mtDNA and miRNA in neuro-inflammation. The cartoon provides a schematic description of how mtDNA and mitomiR may
behave as a single entity to promote neuro-inflammation. mitomiRs may derive either from cytosolic miRNA/pre-miRNA exported and processed within mitochondria
(1a) or directly from mtDNA (1b). mitomiRs disrupt the respiratory chain complexes (2) and increase ROS production (3) thus producing mitochondrial damage,
mitomiR dysregulation (4a), mtDNA fragmentation (4b) and spreading in the cytosol and further, in the extracellular space (5a). In the cytosol, mitomiRs repress a wide
array of genes, among which those encoding for mitophagy (5b), thus exacerbating mitochondrial damage and cell stress. This enhances the extracellular release of
mitomiRs and mtDNA (5a). In addition, both mitomiR and mtDNA behave as DAMPs to initiate an inflammatory response already within neurons and promote the
release of pro-inflammatory cytokines (5c). In the extracellular space, mitomiRs and ccf-mtDNA spread into microglia (6a) to activate inflammation and again, to
promote mitochondrial damage. This translates into fragmentation of mtDNA within glial cells and further release of cff-mtDNA and mitomiRs. Thus, these fragments
along with pro-inflammatory molecules exacerbate the inflammatory response at the level of tissue stroma, which is magnified by the massive leucocyte infiltration and
cytokines release fostered by the leakage of blood brain barrier (BBB). At the same time, ccf-mtDNA and mitomiRs cross the ependymal wall to reach the CSF (6b)
and then the blood, where they are detectable as biomarkers of neuro-inflammation.
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THE CROSSTALK BETWEEN miRNAs
AND MITOCHONDRIA IN
NEURO-INFLAMMATION
The foregoing discussion is centered on the potential role
of ccf-mtDNA as an emerging biomarker of neurological
disorders. However, it is mandatory to relate the neuro-
inflammatory significance of ccf-mtDNA to other, well-known
circulating fragments of nucleic acids, namely micro RNAs
(miRNAs). Briefly, miRNAs are single-stranded, non-coding
RNA fragments, which behave as post-transcriptional gene
modulators by inhibiting messenger RNA (mRNA) translation
or promoting their degradation. Remarkably, recent studies
demonstrated that besides nuclear and cytosolic compartments,
miRNAs are found within mitochondria (70, 71). These
latter are named mitomiRs and include miR-155, miR-181c,
miR142-3p/5p and miR146a. It is remarkable that, mitomiRs
possess a double origin: (i) they are nuclear genome-derived
cytosolic miRNA precursors, exported and processed within
mitochondria, and/or (ii) they originate directly from mtDNA
(72). This issue integrates mtDNA and miRNA in single entities,
which may be dysregulated in a variety of CNS disorders
including AD, PD and MS. Oxidative stress, which is tightly
bound to mitochondrial function and integrity, is one of
the leading causes of RNA oxidation and miRNA pathway
dysregulation (73, 74). This suggests that, miRNA dysregulations
may derive frommitochondrial damage (Figure 2). Alternatively,
miRNA dysregulations occurring in the nucleus or cytosol
may translate into mitochondrial and mtDNA alterations once
these miRNA translocate within mitochondria. In any case,
miRNA dysregulations produce mitochondrial dysfunction via
repression of local mtDNA transcription (75). For instance,
miR-13a and miR-181c impair cytochrome oxidase complex
I and III, leading to a massive increase in ROS, which may
lead to mtDNA fragmentation. This is key for spreading
mtDNA fragments from mitochondria within and outside
of the cell, and for releasing mitomiRs as well. In fact,
mitochondria are the main vehicles, which deliver miRNAs
toward intracellular compartments to modulate expression of
a broad array of genes (76). Such an abnormal spreading of
miRNAs within the cytosol suppresses mitophagy (71, 77), thus
impeding the removal of damaged mitochondria, mtDNA and
miRNAs. An imbalance between mitochondrial clearance and
biogenesis occurs in several neurological disorders (78–80).
In line with this, just like ccf-mtDNA, degradation-resistant
miRNAs circulate in extracellular fluids within exosomes [Figure
2, (81, 82)]. Again, circulating miRNAs such as miR-155,
miR 146a and let-7 are implicated in neuro-inflammation by
acting as DAMPs to activate TLR7 (83–86) in a way, which is
reminiscent of ccf-mtDNA. This appears not to be coincidental
when considering that, these DAMP-like miRNAs reside in
mitochondria and their activity is elicited by NF-κB, (which
in turn is induced by mtDNA fragments). These findings
suggest that the commonalities between mtDNA and miRNAs
as potential biomarkers for neuro-inflammatory disorders are
tightly bound to their mitochondrial nature. A dysregulation
of miRNAs, mitomiRs, and mtDNA perturbs mitochondria and
affects the immune response in the brain. In turn, mitochondrial
damage starts the spreading of membrane-free or exosomal
constituents to promote inflammation at distant sites Figure 2.
At first glance, it appears that a broad range of effects produced
by miRNAs may not allow for a direct correlation with
neuro-inflammation when compared with a quite specific role
of ccf-mtDNA. Nonetheless, the interaction between miRNA,
mitochondria and circulating mtDNA fragments should be
statistically integrated to comprehend their role as biomarkers
of neuro-inflammation.
CONCLUSIONS
These findings cast the hypothesis that variations in mtDNA
levels within the CSF may not simply and passively reflect
neuronal integrity, since an active role of mtDNA in the
neurobiology of disease may underlie a specific cascade of neuro-
inflammatory events. This appears to be quite specific for those
neurological disorders, which are triggered by inappropriate
immune responses. An active role of extracellular mtDNA is
more intriguing than a mere index of neuronal integrity. In
fact, there are neurological conditions where a frank neuronal
loss occurs without variations in mtDNA levels. This is the
case of Creutzfeldt-Jakob disease (CJD), in which massive
neuronal loss occurs despite being mtDNA levels comparable
with controls. Thus, it is likely that the specific molecular
mechanisms underlying early stage of neuronal degeneration
are key in conditioning mtDNA levels. For instance, the
primary involvement of mitochondrial damage producing early
mitochondrial loss may explain why mtDNA levels are reduced
in neurodegenerative conditions such as PD and AD, while
the absence of an early mitochondrial pathology in CJD would
explain the occurrence of normal mtDNA levels. The increase in
mtDNA would require an early, strong involvement of neuro-
immunological mechanisms which does not occur neither in
AD/PD (48, 64) nor in CJD but is prominent in MS. In fact,
mtDNA in MS could be actively released in response to a
stimulus, similar to the release by eosinophils in response to
bacterial infection (27). In this scenario, ccf-mtDNA could be
a primary intrinsic process of neuropathology. Nonetheless, the
role of ccf-mtDNA represents a novel and emerging research field
in the context of neurological disorders, and as such, it remains
rather preliminary and speculative. This calls for further studies
aimed at elucidating whether and how ccf-mtDNA contributes to
and reflects disease onset and progression.
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